Merck KgaA Q2 Profit More Than Doubles; Lifts FY Outlook - Quick Facts

German drug giant Merck KgaA (MKGAY.PK) reported that its second-quarter profit after tax more than doubled to 747 million euros or 1.71 euros per share from 289 million euros or 0.67 euros per share in the prior year.

Earnings per share pre increased by 72.3% to 2.24 euros from the previous year.

EBITDA pre for the quarter grew by 46.7% to 1.6 billion euros from the previous year.

Group net reported sales for the second-quarter increased by 18.2% to 4.9 billion euros compared with the soft, pandemic-impacted year-earlier quarter. Group organic sales increased 23.0% over the year-earlier quarter.

The company increased its fiscal year 2021 EBITDA-pre forecast to a range of 5.6 billion euros - 6.0 billion euros from the prior estimation of 5.4 billion euros - 5.8 billion euros.

The company raised its annual net sales outlook to a range of 18.8 billion euros - 19.7 billion euros from the prior outlook of 18.5 billion euros - 19.5 billion euros.

In the Healthcare business sector, Merck now expects net sales between 1.6 billion euros and 1.8 billion euros in 2022 as a result of new products from the development pipeline. The company previously assumed a sales contribution of around 2 billion euros.

For the Life Science business sector, Merck also expects significant pandemic-related sales in 2022. In the Process Solutions business, the company expects a positive net sales contribution of at least 700 million euros. Previously, at least 500 million euros was assumed.

In the Electronics business sector, in view of the continued strong performance of the semiconductor market, the company anticipates the positive market signals will continue in the medium-term.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teleflex Inc., a provider of medical technologies for critical care and surgery, is recalling Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR, the U.S. Food and Drug Administration said. The Arrow-Trerotola Percutaneous Thrombolytic Device or PTD Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous or AV... Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated..
Follow RTT